Aspreva Pharmaceuticals Corporation engages in the identification, development, and commercialization of approved drugs and drug candidates for new indications. It has two phase III clinical development programs underway to evaluate CellCept, an orally delivered immunosuppressant agent, in the treatment of the autoimmune diseases, such as lupus nephritis and pemphigus vulgaris. The company operates in the United States, Canada, Switzerland, and the United Kingdom. Aspreva Pharmaceuticals was founded in 2001 and is headquartered in Victoria, Canada.